StudyFinder

A Phase 1b Study with IMGN151 Monotherapy and Combinations in Subjects with Gynecologic Cancers

Status: Recruiting

This study is being done to test whether IMGN151, given alone or in combination with approved cancer treatments, is safe, well tolerated, and effective for treating ovarian, fallopian tube, or primary peritoneal cancer. Researchers will also study how the body responds to and processes IMGN151 when given at different doses.

I'm interested

Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of ovarian, fallopian tube, or primary peritoneal cancer
• completed previous cancer treatment before starting the study and have recovered from treatment-related side effects
• able to carry out normal daily activities with little or no assistance
• see link to ClinicalTrials.gov for complete inclusion criteria
Exclusion Criteria:

• prior treatment with an FRα-targeted therapy
• see link to ClinicalTrials.gov for complete exclusion criteria
Interventions:

Drug: Bevacizumab, Drug: Carboplatin, Drug: IMGN151, Drug: Olaparib

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), fallopian tube cancer, ovarian cancer, peritoneal cancer

Study Contact: Deanna Teoh - dkteoh@umn.edu
Principal Investigator: Deanna Teoh
Phase: PHASE2
IRB Number: STUDY00027148
See this study on ClinicalTrials.gov

Back